Curcumin: A Challenge in Cancer Treatment

Authors

  • Purusotam Basnet Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Tromsø,
  • Natasa Skalko-Basnet Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Tromsø,

DOI:

https://doi.org/10.3126/jnpa.v26i1.6631

Keywords:

curcumin, cancer, anti-oxidant, anti-inflammatory, drug delivery

Abstract

Oxidative damage initiates the inflammation and inflammation has been pointed out as the root cause of cancer and various other chronic diseases such as diabetes, hypertension, Alzheimer’s disease, etc. Epidemiological and clinical studies have suggested that cancer could be prevented or significantly reduced by appropriate treatment with anti-oxidant and anti-inflammatory drugs. Therefore, curcumin, a principal component of turmeric (curry spice) exhibiting strong anti-oxidant and anti-inflammatory activities, might be a potential candidate for the prevention and/or treatment of cancer and other chronic diseases. However, curcumin, in spite of its excellent safety profile, multitargeting effects and strong evidences on the molecular levels, could not achieve the desired therapeutic outcome in the past clinical trials, mainly due to its low solubility and poor bioavailability. Curcumin can be developed as a therapeutic drug through improvement in formulation properties or delivery systems, enabling its enhanced absorption and cellular uptake. This review mainly focuses on its anti-oxidant and anti-inflammatory potentials and recent developments in dosage form and delivery systems, opening the possibilities of therapeutic application of curcumin in the prevention and/or treatment of cancer.

DOI: http://dx.doi.org/10.3126/jnpa.v26i1.6631 

JNPA. XXVI(1) 2012 19-47

 

 

 

 

Downloads

Download data is not yet available.
Abstract
2044
PDF
3326

Downloads

Published

2012-08-10

How to Cite

Basnet, P., & Skalko-Basnet, N. (2012). Curcumin: A Challenge in Cancer Treatment. Journal of Nepal Pharmaceutical Association, 26(1), 19–47. https://doi.org/10.3126/jnpa.v26i1.6631

Issue

Section

Articles